Evidence map›Paper›PMID 32971827›Full record

ArticlePharmaceutics2020

Photostability Testing of a Third-Generation Retinoid-Tazarotene in the Presence of UV Absorbers.

Agata Kryczyk-Poprawa, István Zupkó, Péter Bérdi, Paweł Żmudzki, Justyna Popiół, Bożena Muszyńska, Włodzimierz Opoka

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Agata Kryczyk-PoprawaDepartment of Inorganic and Analytical Chemistry, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0001-9125-250X
István ZupkóDepartment of Pharmacodynamics and Biopharmacy, University of Szeged, 6720 Szeged, Hungary.ORCID 0000-0003-3243-5300
Péter BérdiDepartment of Pharmacodynamics and Biopharmacy, University of Szeged, 6720 Szeged, Hungary.
Paweł ŻmudzkiDepartment of Medicinal Chemistry, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0003-3594-1241
Justyna PopiółDepartment of Pharmaceutical Biochemistry, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0002-9825-4302
Bożena MuszyńskaDepartment of Pharmaceutical Botany, Jagiellonian University Collegium Medicum, 30-688 Kraków, Poland.ORCID 0000-0002-5007-1486
Włodzimierz OpokaDepartment of Inorganic and Analytical Chemistry, Jagiellonian University Medical College, 30-688 Kraków, Poland.
Jagiellonian University · PLUniversity of Szeged · HU

Funding

Ministry of Human Capacities, Hungary 20391-3/2018/FEKUSTRATNational Science Center, Poland 2018/02/X/NZ7/01016
6 · The paper itself

Abstract

Exposure of a drug to UV irradiation could affect its physicochemical properties. Hence, photostability testing is essential for topically administered drugs. Tazarotene, a receptor-selective, third-generation retinoid, is commonly used to treat acne vulgaris and psoriasis. In the present study, an in-depth analysis of the photostability of tazarotene in ethanolic solution in the presence of zinc oxide and/or titanium dioxide as well as benzophenone-type UV filters was performed. Eleven presumed products were derived from the photocatalytic degradation of tazarotene using ultra-performance liquid chromatography-tandem mass spectrometry, and transformation pathways were proposed. The degradation process mainly affected the 4,4-dimethyl-3,4-dihydro-2

Indexed as

benzophenonesphotocatalytic degradationphotostability studiestazaroteneTiO2ZnO

Identifiers

PMID32971827
PMCPMC7560049
OpenAlexW3089213114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.